Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up24/7 Wall Street • 3h
Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 EarningsBenzinga • 11h
Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings24/7 Wall Street • Monday
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. PreparednessGlobeNewsWire • Monday
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)GlobeNewsWire • 10/25/26
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/23/26
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss MarketThe Motley Fool • 10/19/26
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit ShareThe Motley Fool • 10/17/26
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer TypesGlobeNewsWire • 10/16/26
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone GrowthBenzinga • 10/12/26
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/12/26
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial ExtensionGlobeNewsWire • 10/12/26